First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET

杜瓦卢马布 医学 放化疗 队列 肺癌 癌症 肿瘤科 内科学 泌尿科 免疫疗法 彭布罗利珠单抗
作者
Johanna E. E. Pouw,Sayed M S Hashemi,Marc C. Huisman,Jessica E. Wijngaarden,Maarten Slebe,Daniela E. Oprea‐Lager,Gerben J.C. Zwezerijnen,Daniëlle J. Vugts,Ezgi B Ulas,Tanja D. de Gruijl,Teodora Radonic,Suresh Senan,C. Willemien Menke‐van der Houven van Oordt,Idris Bahce
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:12 (2): e007659-e007659 被引量:9
标识
DOI:10.1136/jitc-2023-007659
摘要

Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concurrent chemoradiotherapy (CRT). However, it is unclear whether CRT itself upregulates PD-L1 expression. Therefore, this study aimed to explore the changes in the uptake of the anti PD-L1 antibody [89Zr]Zr-durvalumab in tumors and healthy organs during CRT in patients with NSCLC. Methods Patients with NSCLC scheduled to undergo CRT were scanned 7±1 days after administration of 37±1 MBq [89Zr]Zr-durvalumab at baseline, 1-week on-treatment and 1 week after finishing 6 weeks of CRT. First, [89Zr]Zr-durvalumab uptake was visually assessed in a low dose cohort with a mass dose of 2 mg durvalumab (0.13% of therapeutic dose) and subsequently, quantification was done in a high dose cohort with a mass dose of 22.5 mg durvalumab (1.5% of therapeutic dose). Tracer pharmacokinetics between injections were compared using venous blood samples drawn in the 22.5 mg cohort. Visual assessment included suspected lesion detectability. Positron emission tomography (PET) uptake in tumoral and healthy tissues was quantified using tumor to plasma ratio (TPR) and organ to plasma ratio, respectively. Results In the 2 mg dose cohort, 88% of the 17 identified tumor lesions were positive at baseline, compared with 69% (9/13) for the 22.5 mg cohort. Although the absolute plasma concentrations between patients varied, the intrapatient variability was low. The ten quantitatively assessed lesions in the 22.5 mg cohort had a median TPR at baseline of 1.3 (IQR 0.7–1.5), on-treatment of 1.0 (IQR 0.7–1.4) and at the end of treatment of 0.7 (IQR 0.6–0.7). On-treatment, an increased uptake in bone marrow was seen in three out of five patients together with a decreased uptake in the spleen in four out of five patients. Conclusions This study successfully imaged patients with NSCLC with [89Zr]Zr-durvalumab PET before and during CRT. Our data did not show any increase in [89Zr]Zr-durvalumab uptake in the tumor 1-week on-treatment and at the end of treatment. The changes observed in bone marrow and spleen may be due to an CRT-induced effect on immune cells. Trial registration number EudraCT number: 2019-004284-51
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高兴的灰狼完成签到,获得积分10
4秒前
心灵美涵柳完成签到,获得积分10
5秒前
安雯完成签到 ,获得积分10
6秒前
10秒前
AEGUO发布了新的文献求助10
16秒前
尘染完成签到 ,获得积分10
16秒前
DrHHB完成签到 ,获得积分0
17秒前
你盐今虾吗完成签到 ,获得积分10
19秒前
catherine完成签到,获得积分10
19秒前
Benedicta完成签到 ,获得积分10
20秒前
LL完成签到 ,获得积分10
21秒前
眼睛大的元槐完成签到 ,获得积分10
24秒前
Englishroad完成签到 ,获得积分10
26秒前
FFFFF完成签到 ,获得积分10
29秒前
刘刘完成签到 ,获得积分10
30秒前
整齐盼烟完成签到,获得积分10
34秒前
35秒前
刘刘关注了科研通微信公众号
36秒前
紫熊完成签到,获得积分10
37秒前
忆_完成签到 ,获得积分10
38秒前
张文君完成签到 ,获得积分10
40秒前
Sweet完成签到 ,获得积分10
41秒前
灵巧雨寒发布了新的文献求助10
42秒前
独钓寒江雪完成签到 ,获得积分10
43秒前
zp完成签到,获得积分10
44秒前
45秒前
失眠的艳一完成签到,获得积分10
47秒前
辛勤幻竹完成签到,获得积分10
47秒前
AEGUO完成签到,获得积分10
49秒前
清风徐来完成签到,获得积分10
50秒前
HMZ完成签到 ,获得积分10
52秒前
清风徐来发布了新的文献求助10
55秒前
朴实觅夏完成签到 ,获得积分10
1分钟前
韩小小完成签到 ,获得积分10
1分钟前
Xiho完成签到 ,获得积分10
1分钟前
12138发布了新的文献求助10
1分钟前
李y梅子完成签到 ,获得积分10
1分钟前
xiaoyu完成签到 ,获得积分10
1分钟前
1分钟前
flyinthesky完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574253
关于积分的说明 21834609
捐赠科研通 7783129
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357